Dvr Pharma Llp Profile
Key Indicators
- Obligation of Contribution ₹ 2.00 M
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.56 Cr
- Satisfied Charges ₹ 2.50 Cr
- Revenue Growth 94.48%
- Profit Growth -16.30%
- Ebitda 16.76%
- Total Assets 17.84%
About Dvr Pharma Llp
Dvr Pharma Llp (DPL) is 8 Year, 5 Months old Limited Liability Partnership 20 August 2016. Its registered office is in Nalgonda, Telangana, India.
The LLP status is Active, and it has filed its Accounts and Solvency Statement up to 31 Mar 2023 (FY 2022-2023). It's Total Obligation of Contribution is Rs 2.00 M as per MCA.
Company Details
-
Location
Nalgonda, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN/FCRN
AAH-1892
-
Incorporation Date
20 Aug 2016
-
Date of Accounts and Solvency Statement
31 Mar 2023
-
ROC Code
Roc-Hyderabad
-
Company Classification
Limited Liability Partnership
Industry
Who are the key members and board of directors at Dvr Pharma Llp?
Designated Partners (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dilip Dagada
|
Designated Partner | 20-Aug-2016 | Current |
|
Manugunta Reddy
|
Designated Partner | 12-Jan-2022 | Current |
Financial Performance of Dvr Pharma Llp.
Dvr Pharma Llp, for the financial year ended 2021, experienced significant growth in revenue, with a 94.48% increase. The company also saw a substantial fall in profitability, with a 16.3% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dvr Pharma Llp?
Unlock access to Dvr Pharma Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Dagada Hotels Private LimitedDilip Dagada is a mutual person
-
Avistaa Resources Private Limited
Dilip Dagada is a mutual person
Charges (Loans)
₹75.60 M
₹25.00 M
Charges Breakdown by Lending Institutions
- Karur Vysya Bank : 7.06 Cr
- The Karur Vysya Bank Limited : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Feb 2022 | Karur Vysya Bank | ₹4.60 M | Open |
| 08 Jun 2020 | The Karur Vysya Bank Limited | ₹5.00 M | Open |
| 26 Sep 2017 | Karur Vysya Bank | ₹6.60 Cr | Open |
| 06 Oct 2018 | Karur Vysya Bank | ₹2.50 Cr | Satisfied |
How Many Employees Work at Dvr Pharma Llp?
Dvr Pharma Llp has a workforce of 22 employees as of Oct 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dvr Pharma Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dvr Pharma Llp's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
